BPC-157 Dosing Guide: Protocol, Reconstitution & Evidence
BPC-157 is the most widely used peptide in the recovery space, and has been for over a decade. This guide covers what people actually run, the reconstitution math, what the mechanism work shows, and the handful of things genuinely worth watching.
Also known as Body Protection Compound-157, PL 14736
BPC-157 quick start
- Route
- Subcutaneous injection is the most common research-context format. Oral administration is used in gut-focused research on the theory of local action in the GI tract.
- Dose context
- 250–500 mcg/day. This range has been stable across the community for well over a decade — it comes from accumulated practice rather than a dose-finding trial, which makes it the most reliable dosing signal that exists for this compound.
- Measure
- At 2.0 mL reconstitution of a 5 mg vial, 1 unit on a U-100 syringe is 25 mcg. A 250 mcg dose is 10 units.
- Cycle context
- 4–8 weeks is the settled community cycle, then a break. No trial has tested duration, so this reflects what people have found workable rather than a studied limit.
- Status
- Not approved by the FDA for any use. Placed on the WADA Prohibited List (S0, non-approved substances). In 2023 the FDA identified BPC-157 as a category 2 bulk drug substance — meaning significant safety risks were identified for use in compounding.
Dosing context and schedule
What follows is drawn from the published record and from what the community has settled on. Reference points, not prescriptions — your situation is yours.
| Phase | Dose | Volume | Units (U-100) | Note |
|---|---|---|---|---|
| Common research structure | 250 mcg | 0.10 mL | 10 units | Once or twice daily. 5 mg vial in 2.0 mL. |
| Upper cited range | 500 mcg | 0.20 mL | 20 units | The top of the commonly cited range. No human data supports a benefit over lower doses. |
| Localised research use | 250 mcg | 0.10 mL | 10 units | Administered subcutaneously near the area of interest in animal-model designs. |
Cycle structures
| Approach | Duration | Review point | Note |
|---|---|---|---|
| Short structure | 4 weeks | Week 4 | The most common community cycle. Convention rather than a trial finding. |
| Extended structure | 8 weeks | Week 4 and 8 | The upper end of what most people run before taking a break. |
| Continuous use | Not characterised | — | No published human study has examined continuous administration beyond a few weeks. |
What people actually run
The converged protocol
250 mcg once daily, SubQ, injected near the area of interest where that is practical. Some run twice daily through an acute phase and drop back after. 4–8 weeks is the settled cycle length.
This range has held steady for well over a decade across an enormous number of users, which is the strongest dosing signal that exists for this compound. Going higher is common and does not appear to buy much — 500 mcg is the top of what most people find useful.
Local versus systemic is the long-running debate. Injecting near the site is the community default on the theory of local action, but plenty of people inject in the abdomen for convenience and report the same results. No study settles this.
Oral dosing is used specifically for gut issues, where the theory is local action in the GI tract before degradation. For anything musculoskeletal the community view is that oral is not the route.
Almost always stacked with TB-500. The reasoning is local repair plus systemic support, and while no trial has tested the pair, it is probably the most-run peptide combination there is.
What the evidence actually says
The honest picture
Here is the honest shape of it. BPC-157 has fifteen years of heavy real-world use behind it and a large body of mechanism research explaining how it works. What it does not have is a randomised controlled trial — and it almost certainly never will, because it is a 15-amino-acid sequence nobody can patent. No company will spend nine figures proving something they cannot own. That is a fact about how drug development gets financed, not a verdict on whether it works.
What that means practically: tolerability at community doses is about as well established as it gets outside a formal trial, simply through sheer volume of use across a very large number of people over a very long time. Dosing has converged and stayed converged, which rarely happens with something that does nothing. The one thing volume of use genuinely cannot settle is very long-term effects, because slow or diffuse harms never get traced back to their cause. That is the real open question — not whether people can take it, but what a decade of continuous use looks like. Most people cycle for that reason, and cycling is a sensible answer to it.
How it is proposed to work
BPC-157 is a synthetic 15-amino-acid sequence. It is described as a partial sequence of Body Protection Compound, a protein reported to have been isolated from human gastric juice. The parent compound itself is not well characterised in the published literature.
The mechanisms proposed in animal work centre on angiogenesis — the formation of new blood vessels — via upregulation of VEGF signalling, alongside effects on nitric oxide pathways and growth factor receptor expression. Rodent studies have reported accelerated tendon-to-bone healing, protection against NSAID-induced gut damage, and effects on ligament repair.
The important caveat is that a mechanism demonstrated in a rat is a hypothesis in a human, not a finding. None of these pathways have been confirmed to operate the same way at these doses in people.
When to talk to a doctor first
Most people run BPC-157 without incident. These are the specific situations where it is worth a conversation with a clinician before you start — not reasons to rule it out, but reasons to go in with your eyes open.
- If you have an active or suspected malignancy, or a recent cancer history — this is the one that genuinely matters. BPC-157 promotes blood vessel growth, which is the same mechanism a tumour would use to feed itself. Worth a direct conversation with your oncologist rather than a judgement call on your own.
- If you are pregnant or breastfeeding — there is no reproductive data in either direction, so the sensible move is to wait.
- If you compete in a tested sport — BPC-157 is on the WADA Prohibited List and a positive finding carries real sanctions. Better to know now than after.
- If the injury is not shifting at all — BPC-157 supports healing, but it cannot tell you what is wrong. Pain that will not budge deserves imaging and a clinician alongside it, not instead of it.
What to expect
Most of what people notice is mild and settles within the first week or two. The list below is ordered by how often it actually comes up, so you know what is routine and what is worth paying attention to.
Common, and usually settles
- Injection site reactions — redness, mild swelling, transient stinging.
- Light-headedness shortly after administration, reported anecdotally.
Less common
- Headache.
- Nausea, more often reported with oral administration.
- Changes in appetite.
Rare — stop and get advice
- Nothing serious has emerged from community use, and that use runs to well over a decade at scale — which is the most meaningful safety signal available for a compound nobody has funded a trial on.
- The one open question is angiogenesis. BPC-157 promotes blood vessel formation, which is how it helps tissue heal and also, in principle, how a tumour would be fed. Nobody has established or excluded this in humans. It is the reason to skip it if you have an active or recent malignancy, and not much of a consideration if you do not.
Reconstitution guide
BPC-157 ships as a lyophilised powder and gets mixed with bacteriostatic water before use. How much water you add sets the concentration, which sets how many syringe units make up each dose. One unit on a U-100 syringe is 0.01 mL — the tables below do the arithmetic for the vial sizes you are most likely to be holding.
10mg vial most common
| Water added | Concentration | 200mcg | 500mcg |
|---|---|---|---|
| 2mL (common) | 5 mg/mL | 0.04 mL 4 units | 0.10 mL 10 units |
| 3mL | 3.33 mg/mL | 0.06 mL 6 units | 0.15 mL 15 units |
5mg vial
| Water added | Concentration | 200mcg | 500mcg |
|---|---|---|---|
| 2mL (common) | 2.5 mg/mL | 0.08 mL 8 units | 0.20 mL 20 units |
| 3mL | 1.67 mg/mL | 0.12 mL 12 units | 0.30 mL 30 units |
Standard steps
- Inspect the vialConfirm the label and that the powder cake is intact. Do not use a cracked or compromised vial.
- Let it reach room temperatureSitting out for a few minutes reduces condensation inside the vial when the seal is broken.
- Disinfect both stoppersWipe the compound vial and the bacteriostatic water vial with a fresh alcohol swab and let them air-dry.
- Draw the bacteriostatic waterUse a sterile syringe to draw the volume you have chosen from the reconstitution table.
- Add the water down the vial wallInject slowly so it runs down the inside wall rather than spraying directly onto the powder. This limits foaming.
- Dissolve gentlySwirl or roll the vial between your hands until the cake dissolves. Never shake — agitation damages peptide bonds. The solution should end up clear.
- Label and refrigerateWrite the reconstitution date and concentration on the vial. Store at 2–8°C. Do not freeze.
Timeline and monitoring
- Days 1–7No reliable published human timeline exists. Anecdotal reports commonly describe changes in this window, but anecdote and placebo are indistinguishable without a control.
- Weeks 2–4Where most people take stock and decide whether to continue.
- Weeks 4–8The upper bound of typical research-context duration.
- After useNo withdrawal or rebound effect has been described in the literature.
Bloodwork worth discussing
Markers a clinician may consider relevant before or during a protocol. This is context for a conversation, not a self-ordering list.
| Marker | Why it is relevant |
|---|---|
| Complete blood count | General baseline. Not specific to BPC-157, but useful before any extended protocol. |
| Comprehensive metabolic panel | Baseline liver and kidney function. |
| Age-appropriate cancer screening | Given the angiogenic mechanism, being current on screening appropriate to your age and history is a reasonable precaution to discuss with a clinician. |
Supplies by cycle length
A 5 mg vial provides 20 doses at 250 mcg, or 10 doses at 500 mcg.
| Cycle length | Vials | Syringes | BAC water | Planning note |
|---|---|---|---|---|
| 4 weeks | 2 vials | 28 syringes | 1 × 10 mL bottle | Once daily at 250 mcg. |
| 8 weeks | 3 vials | 56 syringes | 1 × 10 mL bottle | Once daily at 250 mcg. |
| 8 weeks (twice daily) | 6 vials | 112 syringes | 2 × 10 mL bottles | Twice daily at 250 mcg. |
What the research record contains
The BPC-157 literature is almost entirely preclinical. A large body of rodent work — much of it from a single research group in Croatia — reports effects on tendon, ligament, muscle, nerve and gastrointestinal healing across many injury models.
What is missing is the part that matters: adequately powered, randomised, controlled human trials. As of this writing there is no published Phase 2 or Phase 3 efficacy data in humans for any indication.
In 2023 the FDA placed BPC-157 in category 2 of its bulk drug substances review — substances for which significant safety risks were identified — which effectively bars its use in compounded preparations in the United States.
This does not mean BPC-157 does nothing. It means nobody has demonstrated what it does in humans, at what dose, for how long, or with what risk. Those are four separate unknowns.
Storage and handling
- Lyophilised powder: refrigerate at 2–8°C. Stable for extended periods when kept dry, cold and out of light.
- Once reconstituted: refrigerate only. Do not freeze — ice crystal formation damages peptides.
- Reconstituted solution is commonly used within 30 days. Bacteriostatic water contains benzyl alcohol, which is what allows multi-dose use; sterile water does not and should be treated as single-use.
- Keep out of direct light. Label the vial with the reconstitution date and concentration — guessing later is how dosing errors happen.
Troubleshooting
The powder did not fully dissolve.
Swirl gently and give it several minutes. Never shake — agitation shears peptide bonds. If particulate remains after the cake has had time to dissolve, do not use the vial.
The solution looks cloudy.
A properly reconstituted peptide solution is clear. Cloudiness suggests degradation or contamination. Discard it.
My dose is under 5 units and hard to measure.
Reconstitute with more water. Using 3.0 mL instead of 1.0 mL triples the volume per dose and makes the draw far easier to read accurately.
I missed a day.
There is no established catch-up protocol because there is no established protocol. Resume as before rather than doubling.
Regulatory status
BPC-157 is not approved by the FDA for any therapeutic use, in the United States or elsewhere.
In September 2023 the FDA published its review of bulk drug substances nominated for use in compounding, placing BPC-157 in category 2 — substances with significant safety risks. Compounding pharmacies in the US cannot lawfully prepare it.
BPC-157 appears on the WADA Prohibited List under S0 (non-approved substances), prohibited at all times both in and out of competition.
Material sold online is generally labelled "for research use only, not for human consumption". That label is a legal position taken by the seller, not a statement about purity or identity.
How it compares
| Compared with | Difference that matters |
|---|---|
| TB-500 | The most-run pairing in the space — local repair plus systemic support is the reasoning. No trial has tested the combination, but between them they have decades of accumulated use. |
| Conventional care | For a specific injury, the interventions with actual human evidence are progressive loading, physical therapy and time. BPC-157 has none of that evidence base behind it. |
Frequently asked questions
Does BPC-157 actually work?
In rodents, a large number of studies report healing effects across many tissue types. In humans, nobody knows, because the trials have not been done. Anyone who tells you definitively either way is going beyond the evidence.
Is oral BPC-157 effective?
Oral dosing is used in gut-focused research on the theory that it acts locally in the GI tract before being degraded. Systemic absorption from oral administration is likely to be poor. There is no human bioavailability study to settle this.
How long can it be used?
No study establishes a safe duration. Research-planning structures typically describe 4–8 weeks, but that convention comes from community practice rather than data.
Why is it banned by WADA?
WADA prohibits non-approved substances as a class under S0 — anything without regulatory approval for human therapeutic use. It is not a statement about performance benefit.
Is it safe?
Unknown. No controlled human safety study has been published. The specific unresolved concern is the angiogenic mechanism and its relationship to tumour growth.
References
- Bulk Drug Substances Nominated for Use in Compounding — Category 2U.S. Food and Drug Administration, 2023
- WADA Prohibited List — S0 Non-Approved SubstancesWorld Anti-Doping Agency
This page is an educational research reference and is not medical advice. BPC-157 is not approved for human use in any jurisdiction. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.